Autolus Therapeutics

Yahoo Finance • 7 days ago

Autolus Therapeutics to Participate in Upcoming Investor Conferences

LONDON and GAITHERSBURG, Md., April 07, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies,... Full story

Yahoo Finance • 10 days ago

Mizuho Lowers its Price Target on Autolus Therapeutics plc (AUTL) to $10 from $12

Autolus Therapeutics plc (NASDAQ:AUTL) is one of the 7 Fastest Growing European Stocks to Invest In. On March 31, 2026, Mizuho lowered its price target on Autolus Therapeutics plc (NASDAQ:AUTL) to $10 from $12 previously and maintained an... Full story

Yahoo Finance • 18 days ago

European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading

European equities traded in the US as American depositary receipts were little changed late Friday m PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 19 days ago

Pre-Market Earnings Report for March 27, 2026 : CCL, TMC, CUK, KOPN, SBC, AUTL, SNWV, HUMA, SLE

The following companies are expected to report earnings prior to market open on 03/27/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Carnival Corporation (CCL)is reporting for the quarter ending Februa... Full story

Yahoo Finance • 29 days ago

Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026

LONDON and GAITHERSBURG, Md., March 16, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies,... Full story

Yahoo Finance • 2 months ago

Spotlight On Silence Therapeutics And 2 Other Promising Penny Stocks

As February begins, the U.S. stock market is showing strength, with major indexes like the Dow Jones and S&P 500 posting significant gains. In this context of rising indices, investors often look for opportunities that may offer growth pot... Full story

Yahoo Finance • 3 months ago

Needham ups Autolus target, names top pick for 2026

Needham raised the firm’s price target on Autolus Therapeutics (AUTL) to $11 from $10 and keeps a Buy rating on the shares. The firm also names Autolus a top pick for 2026. While Aucatzyl’s launch has been impressive with $76M in sales, in... Full story

Yahoo Finance • 4 months ago

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

European equities traded in the US as American depositary receipts were tracking higher late Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 4 months ago

3 Promising Penny Stocks With Market Caps Over $70M

With the recent surge in U.S. stock markets following the Federal Reserve's interest rate cuts, investors are keenly observing how these changes might impact various sectors. While major indices like the S&P 500 and Dow Jones have shown si... Full story

Yahoo Finance • 4 months ago

Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025

Data show deep, durable responses in the 50 million cell dose level cohort; initial data suggest substantial early improvement in three patients dosed with 100 million cellsAll patients show deep B-cell depletion after infusion, suggesting... Full story

Yahoo Finance • 4 months ago

Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025

Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of high-grade cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity s... Full story

Yahoo Finance • 5 months ago

NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹

LONDON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that t... Full story

Yahoo Finance • 5 months ago

Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

LONDON and GAITHERSBURG, Md., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell thera... Full story

Yahoo Finance • 5 months ago

Autolus outlines margin improvement and market share growth focus while expanding AUCATZYL to 60 U.S. centers

Earnings Call Insights: Autolus Therapeutics plc (AUTL) Q3 2025 MANAGEMENT VIEW * CEO Christian Itin reported the launch of AUCATZYL in the U.S. has reached market leadership in relapsed/refractory B-ALL, with broad access and reliable... Full story

Yahoo Finance • 5 months ago

November 2025's Promising Penny Stocks To Watch

As the Dow Jones Industrial Average reaches an all-time high amid optimism over the potential end of a prolonged U.S. government shutdown, investors are keenly observing market dynamics and seeking opportunities across various sectors. Pen... Full story

Yahoo Finance • 5 months ago

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025

LONDON and GAITHERSBURG, Md., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell thera... Full story

Yahoo Finance • 6 months ago

Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025

Data from the Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with no ICANS or high-grade CRS; 50 million cell dose selected for Phase 2 pivotal studyPreliminary efficacy... Full story

Yahoo Finance • 6 months ago

Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis

LONDON and Gaithersburg, Md., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell thera... Full story

Yahoo Finance • 6 months ago

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON and GAITHERSBURG, Md., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell thera... Full story

Yahoo Finance • 7 months ago

Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025

LONDON and GAITHERSBURG, Md., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell ther... Full story